Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Restoration of p53 function leads to tumour regression in vivo


Tumorigenesis is a multi-step process that requires activation of oncogenes and inactivation of tumour suppressor genes1. Mouse models of human cancers have recently demonstrated that continuous expression of a dominantly acting oncogene (for example, Hras, Kras and Myc) is often required for tumour maintenance2,3,4,5; this phenotype is referred to as oncogene addiction6. This concept has received clinical validation by the development of active anticancer drugs that specifically inhibit the function of oncoproteins such as BCR-ABL, c-KIT and EGFR7,8,9,10. Identifying additional gene mutations that are required for tumour maintenance may therefore yield clinically useful targets for new cancer therapies. Although loss of p53 function is a common feature of human cancers11, it is not known whether sustained inactivation of this or other tumour suppressor pathways is required for tumour maintenance. To explore this issue, we developed a Cre-loxP-based strategy to temporally control tumour suppressor gene expression in vivo. Here we show that restoring endogenous p53 expression leads to regression of autochthonous lymphomas and sarcomas in mice without affecting normal tissues. The mechanism responsible for tumour regression is dependent on the tumour type, with the main consequence of p53 restoration being apoptosis in lymphomas and suppression of cell growth with features of cellular senescence in sarcomas. These results support efforts to treat human cancers by way of pharmacological reactivation of p53.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Generation of the p53-LSL allele.
Figure 2: p53 restoration leads to tumour regression in vivo.
Figure 3: p53 restoration in lymphomas leads to apoptosis.
Figure 4: p53 restoration in sarcomas leads to growth suppression with features of cellular senescence.


  1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000)

    CAS  Google Scholar 

  2. Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999)

    ADS  CAS  Article  Google Scholar 

  3. Jain, M. et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297, 102–104 (2002)

    ADS  CAS  Article  Google Scholar 

  4. Fisher, G. H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249–3262 (2001)

    CAS  Article  Google Scholar 

  5. Pelengaris, S., Khan, M. & Evan, G. I. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109, 321–334 (2002)

    CAS  Article  Google Scholar 

  6. Weinstein, I. B. Cancer. Addiction to oncogenes–the Achilles heel of cancer. Science 297, 63–64 (2002)

    CAS  Article  Google Scholar 

  7. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001)

    CAS  Article  Google Scholar 

  8. Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472–480 (2002)

    CAS  Article  Google Scholar 

  9. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004)

    CAS  Article  Google Scholar 

  10. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004)

    ADS  CAS  Article  Google Scholar 

  11. Sherr, C. J. Principles of tumor suppression. Cell 116, 235–246 (2004)

    CAS  Article  Google Scholar 

  12. Olivier, M. et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19, 607–614 (2002)

    CAS  Article  Google Scholar 

  13. Bykov, V. J. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med. 8, 282–288 (2002)

    CAS  Article  Google Scholar 

  14. Snyder, E. L., Meade, B. R., Saenz, C. C. & Dowdy, S. F. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol. 2, E36 (2004)

    Article  Google Scholar 

  15. Branda, C. S. & Dymecki, S. M. Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev. Cell 6, 7–28 (2004)

    CAS  Article  Google Scholar 

  16. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215–221 (1992)

    ADS  CAS  Article  Google Scholar 

  17. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1–7 (1994)

    CAS  Article  Google Scholar 

  18. Indra, A. K. et al. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ERT and Cre-ERT2 recombinases. Nucleic Acids Res. 27, 4324–4327 (1999)

    CAS  Article  Google Scholar 

  19. Soriano, P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nature Genet. 21, 70–71 (1999)

    CAS  Article  Google Scholar 

  20. Kemp, C. J., Wheldon, T. & Balmain, A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet. 8, 66–69 (1994)

    CAS  Article  Google Scholar 

  21. Collado, M. et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005)

    ADS  CAS  Article  Google Scholar 

  22. Lowe, S. W. & Sherr, C. J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77–83 (2003)

    CAS  Article  Google Scholar 

  23. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature advance online publication, doi:10.1038/nature05529 (24 January 2007)

  24. Zhang, L. et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60, 3655–3661 (2000)

    CAS  PubMed  Google Scholar 

  25. Teodoro, J. G., Parker, A. E., Zhu, X. & Green, M. R. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 313, 968–971 (2006)

    ADS  CAS  Article  Google Scholar 

  26. Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nature Genet. 37, 1289–1295 (2005)

    CAS  Article  Google Scholar 

  27. Christophorou, M. A. et al. Temporal dissection of p53 function in vitro and in vivo. Nature Genet. 37, 718–726 (2005)

    CAS  Article  Google Scholar 

  28. Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214–217 (2006)

    ADS  CAS  Article  Google Scholar 

  29. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004)

    ADS  CAS  Article  Google Scholar 

  30. Haupt, S. & Haupt, Y. Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin. Cancer Biol. 14, 244–252 (2004)

    CAS  Article  Google Scholar 

  31. Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847–860 (2004)

    CAS  Article  Google Scholar 

Download references


We thank N. Willis for helping to generate the LSL mice, H. Zheng for imaging mice, G. Wojtkiewicz for generating the movies with three-dimensional reconstruction, D. Crowley for help with histology, R. Bronson for reviewing the pathology, and M. Hemann for suggestions. A.V. is grateful to D. Ventura and G. Terranova for continuous support and encouragement. This work was supported by the Howard Hughes Medical Institute (T.J.), NCI (T.J., R.W., D.G.K.), and partially by a Cancer Center Support grant from the NCI (M.I.T.), the American Italian Cancer Research Foundation (A.V.), and the Leaf fund (D.G.K.). T.J. is the David H. Koch Professor of Biology and a Daniel K. Ludwig Scholar. D.A.T. is a Rita Allen Foundation Scholar.

Author Contributions A.V., D.G.K. and T.J. designed the experiments and wrote the paper. D.T. generated the p53-LSL mice and M.E.M. generated and characterized the Cre-ERT2 mice, determined the optimal Tamoxifen dosage, assisted with histopathological analysis and commented on the manuscript. A.V., D.G.K. and L.L. derived and characterized the tumour cell lines. A.V. performed the immunostainings, the TUNEL assays the SA-β-Gal stainings and the western blottings. A.V., D.K. and L.L. performed the tamoxifen intraperitoneal injections. E.E.R. derived the MEFs. L.L. and J.N. maintained the mouse colony and genotyped the animals. J.G. and D.G.K. evaluated the magnetic resonance images, J.G. supervised the magnetic resonance imaging, generated the three-dimensional reconstructions and determined tumour volumes. R.W. optimized in vivo imaging protocols, reviewed imaging data, discussed the results, and commented on the manuscript.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Tyler Jacks.

Ethics declarations

Competing interests

Reprints and permissions information is available at The authors declare no competing financial interests.

Supplementary information

Supplementary file 1

This file contains Supplementary Methods, Supplementary Figures 1, 3, 5, 6 and 7 with legends. The Supplementary Figures 2 and 4 are represented as movie files. (PDF 3041 kb)

Supplementary file 2

This file contains movies of 3D reconstructions indicated in the main text as Supplementary Figures 2. (AVI 6872 kb)

Supplementary file 3

This file contains movies of 3D reconstructions indicated in the main text as Supplementary Figures 2. (AVI 7219 kb)

Supplementary file 4

This file contains movies of MRIs indicated in the main text as Supplementary Figures. (MOV 169 kb)

Supplementary file 5

This file contains movies of MRIs indicated in the main text as Supplementary Figures 2. (MOV 185 kb)

Supplementary file 6

This file contains movies of MRIs indicated in the main text as Supplementary Figures 2. (MOV 159 kb)

Supplementary file 7

This file contains movies of MRIs indicated in the main text as Supplementary Figures 2. (MOV 163 kb)

Supplementary file 8

This file contains movies of 3D reconstructions indicated in the main text as Supplementary Figures 4. (AVI 6481 kb)

Supplementary file 9

This file contains movies of 3D reconstructions indicated in the main text as Supplementary Figures 4. (AVI 6200 kb)

Supplementary file 10

This file contains movies of MRIs indicated in the main text as Supplementary Figures 4. (MOV 243 kb)

Supplementary file 11

This file contains movies of MRIs indicated in the main text as Supplementary Figures 4. (MOV 341 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ventura, A., Kirsch, D., McLaughlin, M. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing